Serendex becomes US-owned
Danish biotech company Serendex said this week that it had been acquired by US-based Savara Pharmaceuticals. It marks the end of a prolonged period of financial instability for the company, which will remain in Hørsholm north of Copenhagen as a subsidiary of the American group.
BY LOUISE WENDT JENSEN
It might be pushing it too far to say that Serendex has been saved by the bell as the biotech company has enough money to last the rest of the year, but as CEO Kim Arvid Nielsen has previously pointed out, it has been necessary for the company to find a long-term solution to its financial woes.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Serendex CEO: Disappointing share price development
For abonnenter
Serendex considers Norwegian IPO
For abonnenter
